BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
3) The rationale for a multivariable prediction model should be elaborated on. Does one want to develop a new model or validate existing ones? Or extend existing models and do a decision curve analysis? 4) Source of data should not only be mentioned in the abstract, but receive extensive attention in the methods (and materials) section 6) Reconsider issues concerning the outcome. 7) More details are needed about the predictors of the models. 8) Please reconsider the sample size estimation based on the outcome. 9) Missing data are a bit neglected in the protocol, simply working with a complete case approach (handling lost to follow-up as missing) is not very sound. Think about applying multiple imputation techniques. 10) Please look carefully again at the methods and maybe employ a statistician or an epidemiologist to help out. 12) If doing validation, then differences from the development data must be carefully looked at.
As a minor point, on page 17 it is stated: "Because Radiometer troponin T is less sensitive than Abbott ARCHITECT hs-troponin I and therefore, we generally prioritize the result of hs-troponin I if the results of the two types troponin are discordant". Logically speaking then, it would seem that Radiometer troponin T is irrelevant. If so, why is it presented in the first place?
On page 18, lines 20 to 30: Is there a danger of affecting the results inappropriately?
Please look at the format of the reference list. For example the journals are not always abbreviated correctly and references 4, 5, and 28 look incomplete.
VERSION 1 -AUTHOR RESPONSE

Reviewer: 1
Reviewer Name: Dr João Gonçalves Almeida 1 -What is the reason to include patients without chest pain? Response 1. Thank you for your query. A substantial proportion, up to 50%,(1) of patients with myocardial infarction present to the emergency department with non-chest pain complaints. Because the purpose of our study is to evaluate diagnostic strategies for all patients suspected of myocardial infarction, excluding patients without chest pain harms the representativeness. The risk of myocardial infarction may be different between patients with chest pain and without chest pain, and we will perform the sensitivity analysis according to the presence of chest pain as stated in the "Sensitivity analysis" section (page 20, line 25).
Response 2. Thank you for your valuable question. According to guidelines, if clinical risk estimation is high risk or ECG shows ischemic changes, we observe or admit those patients and proceed to further investigation even when some sets of troponin are negative.(2, 3) However, we did not include unstable angina into the composite outcome, because patients with unstable angina have a substantially lower risk of death and subsequent myocardial infarction, and benefit less from treatment than do patients with NSTEMI, even in the era of contemporary troponin and much less in the era of high-sensitivity troponin. (3) (4) (5) Some experts say it may be better not to categorize unstable angina with acute myocardial infarction anymore. (6, 7) Furthermore, a substantial number of recent studies of prediction-rules and hs-troponin-based strategies did not include unstable angina in their clinical endpoints. (8) (9) (10) (11) 3 -Since the GRACE score is recommended by American and European guidelines, I think the inclusion of a strategy based on this score would be useful.
Response 3. Thank you for your valuable advice. Since all the variables of the GRACE score were included in our case report form, we have added the GRACE score to the index tests (page 15, line 22 -page 16, line 4).
5 -There are some limitations that should be mentioned: since the population is only from Japan, the generalization of the results will be limited; I think the evaluation of the clinical outcome by telephone is a major limitation, since you will miss patients with asymptomatic myocardial infarction (diabetic patients for example), the follow-up with ECG or even echocardiogram would increase the sensitivity for the outcome.
Response 5. Thank you for your comment. Yes, I agree with you, and I have added these points to the protocol (page 4, line 20 -25). However, we think it is very unlikely that patients will have an MI and not reattend hospital, especially in Japan where the access to hospital is good in both medical insurance system and geographical conditions. 6 -Minor spelling suggestions: "electronic cardiogram (ECG)" to "electrocardiogram (ECG)"; "However, in about 80 to 90% of patients presenting to EDs for a possible MI, the presenting symptoms are not cardiac in origin." I suggest you rephrase this affirmation and include a reference to support it.
Response 6. Thank you for pointing out my spelling mistake. I have corrected it. I rephrased the sentence as follows, "However, between 75% and 95% patients presenting to the EDs with symptoms suggestive of MI did not have MI(1, 12)" (page 5, line 11 -12 The original publication for this strategy [2] proposes a pathway with an application of a highsensitivity cardiac troponin I assay that incorporates a risk stratification threshold of < 5ng/L at presentation and no change (<3 ng/L) at repeated troponin after 3 hours from arrival to the emergency department. In the adopted strategy, the Authors use the time frame of 2 hours from presentation (0h) to the next troponin assessment when hs-troponin I at 0h is ?5 and ? 26.2 ng/L or in case the symptom onset occurred < 2 hours. To rule out an acute myocardial infarction, the Authors consider modified, that is, the 2-hour period for the original delta hs-troponin I <3 ng/L, at the same time maintaining the originally applied hs-troponin I concentration threshold ?26.2 ng/L after 3 hours from presentation.
If the algorithm was modified for the High-STEACS pathway strategy, it should probably be marked in the description of the model. Response 2. Thank you for your in-depth analysis and comment. I originally excluded the High-STEACS pathway due to the same reason as you. However, I asked the author of the rule, Andrew Chapman, and he said it usually took one hour to obtain the first blood sample, so the second sample was taken two hours apart (after three hours from arrival) in reality. Therefore, I did not make any modification to the original rule. This issue should be explained and I have added some sentences to my protocol (page 16, line 10 -14).
Response 3. Thank you very much for pointing out my mistake. I have corrected it accordingly (page 6, line 5).
_________________________________________________________________________________ ____________________________
Reviewer: 3
Reviewer Name: Dr Michael Edlinger 1 -The rationale for or the reasons why the hs-troponin-based strategies should be evaluated and compared remain somewhat unclear.
Response 1. Thank you for your valuable suggestion. We agree with you and have revised the "Background" section to explain the significance of hs-troponin-based strategies (page 7, line 1 -8).
2 -And actually then also making comparisons with prediction rules and clinical impressions seems a bit too much.
Response 2. Thank you for your suggestion. Our study is exploratory, and we do not have a strong prior hypothesis regarding which strategy is better. Thus, we would like to validate existing models comprehensively. We have revised some sentences in the "Rationale for the study" section (page 7, line 15 -17) to explain it.
3 -Have the authors considered problems of possible biases, since there is no randomisation?
In which manner are the hs-troponin-based strategies (to be) chosen for each patient?
Response 3. Because our study is a diagnostic study and we are not in the stage of hypothesis testing to prove clinical effectiveness of diagnostic strategies, we think we do not need to randomize patients to ensure comparability. We have designed our case report forms to include all predictors of all the index tests, and all the index tests are applied to a patient when we analyze data. Which diagnostic strategy to choose is up to the treating physicians when they see patients in the emergency department (page 11, line 21 -22, section "Clinical assessments").
How representative are the five hospitals?
Response 4. Thank you for the important question. All emergency departments of five study hospitals treat all kinds of patients, and this ensures the representativeness of the emergency department. Although four of the five study hospitals are in a specific region in Japan, there are few reports that patients' characteristics in the region differ from those in other regions, and we will be enrolling further hospitals in other regions in Japan. Therefore, we believe that our study population will be representative. We would like to discuss this issue in the "Discussion" section of our main analysis article.
5 -1. The section on the data analysis is rather incomplete, especially because the outcome variables are not optimally adequate. In a diagnostic study one would want to predict the diagnosis and for the accuracy the performance (discrimination, calibration, and validation) is important.
Response 5 -1. Thank you for providing your valuable inputs. Because almost all index tests are only for discrimination, we will validate the discrimination performance only, and therefore will not evaluate calibration. Please view the referenced articles of diagnostic models in the "Index tests" section (page 14 -17).
5 -2. The way things are presented it is ambiguous how the various models are to be compared statistically and multiple testing might be a problem.
Response 5 -2. Thank you for your insightful comment. We have added a few sentences regarding the statistical models to compare NPV, sensitivity, and effectiveness (page 20, line 4 -5) . Please see our response 2 as well. Because our study is exploratory, we will not adjust for multiple comparisons.
Quite nicely the TRIPOD checklist was included. However, some very important matters have somehow been overlooked:
1) The title is not appropriate.
Response 1) Thank you for your valuable suggestion. We have changed the title to clarify that our study is a validation study as follows, "A comprehensive validation of very early rule-out strategies for non-ST elevation myocardial infarction in emergency departments: protocol for a multicenter prospective cohort study" (page 1, line 1 -3).
2) The abstract is sub-optimal.
Response 2) Thank you for your suggestion. We have revised a sentence accordingly to clarify our objective and study design as follows, "Therefore, our objective in this prospective cohort study is to comprehensively validate the diagnostic accuracy of clinical impression-based strategies, predictionrules, and hs-troponin-based strategies for ruling-out NSTEMIs" (page 3, line 7 -10). Because this article is a study protocol, we think that sections on statistical analysis, results, and conclusions are not necessary for the abstract. Otherwise, we have explained all the items which the TRIPOD requires such as the setting, participants, sample size, predictors, and outcome.
3) The rationale for a multivariable prediction model should be elaborated on. Does one want to develop a new model or validate existing ones? Or extend existing models and do a decision curve analysis?
Response 3) Thank you for your valuable comments. Please refer to our response 2 which explains that our purpose is to validate existing models. Because we will validate only the discrimination performance, as we explained in our response 5 -1, we have observed that we cannot use a decision curve analysis. We have deleted the decision curve analysis from the "Data analysis" section (page 20).
4) Source of data should not only be mentioned in the abstract, but receive extensive attention in the methods (and materials) section.
Response 4) Thank you for your critical and valuable suggestion. We agree with you and have added a section "Setting" in the methods (page 9, line 2 -7). 6) Reconsider issues concerning the outcome.
Response 6) Because our purpose is only to evaluate the discrimination performance, we think the outcomes are valid. All the original articles of index tests adopted similar outcomes as ours (sensitivity, specificity, positive predictive value, negative predictive value, and effectiveness). Response 8) Thank you for your valuable comment. As we explained in our response 6), we think the outcomes are valid. Our primary purpose is not comparison, but description of the diagnostic accuracy of each model. Therefore, we made the sample size estimation based on accuracy. We chose the clinical impression-strategy for the sample size estimation, because it is supposed to be the most common approach in Japan (page 6, line 9 -10) 9) Missing data are a bit neglected in the protocol, simply working with a complete case approach (handling lost to follow-up as missing) is not very sound. Think about applying multiple imputation techniques.
Response 9) You have raised the important point, however, we think that patients with imputed outcomes should be excluded from analysis anyway, because using imputed outcomes only adds noise to the estimates. (13, 14) We have recognized the significance of lost to follow-up from the beginning. We could follow-up 99% of patients in our preliminary study, and we have made more efforts to prevent it in this study. Therefore, we expect that the number of patients lost to follow-up will be very few. 10) Please look carefully again at the methods and maybe employ a statistician or an epidemiologist to help out.
Response 10) Thank you for your kind suggestion. We have a statistician on our team and will consult him if necessary. 12) If doing validation, then differences from the development data must be carefully looked at.
Response 12) Thank you very much for providing this suggestion. We will certainly evaluate the development data in the "Discussion" section in the article of our primary analysis.
As a minor point, on page 17 it is stated: "Because Radiometer troponin T is less sensitive than Abbott ARCHITECT hs-troponin I and therefore, we generally prioritize the result of hs-troponin I if the results of the two types troponin are discordant".
Logically speaking then, it would seem that Radiometer troponin T is irrelevant. If so, why is it presented in the first place?
Response: Thank you for your comment. We agree with you. We have deleted Radiometer troponin T, and will use each of hs-troponin for the adjudication. We will use the same hs-troponin to adjudicate the final diagnosis as that used for index tests to avoid unequal incorporation bias (page 18, line 11 -18).
Response: Thank you for your suggestion. We apologize but we could not understand what danger could affect the results inappropriately or why. We would be happy if you could explain it more specifically.
Response: Thank you very much for pointing out my mistakes. We apologize for the oversights and we have corrected the references accordingly.
_________________________________________________________________________________ ____________________________
GENERAL COMMENTS
This very interesting and relevant multicenter prospective cohort study, just as other up-to-date studies, e.g. [1] , aims to select the best strategies for rapid ruling-out of AMI at an emergency department, validating them in the East Asian population with emphasis on the performance of the clinical impression-based approach.
The Authors have given the exhaustive response to the reviewer comment.
[ Although four of the five study hospitals are in a specific region in Japan, there are few reports that patients' characteristics in the region differ from those in other regions, and we will be enrolling further hospitals in other regions in Japan. Therefore, we believe that our study population will be representative. We would like to discuss this issue in the "Discussion" section of our main analysis article. ME: So the hospitals involved have not been selected at random. This might compromise the validity to some extent.
5 -1. The section on the data analysis is rather incomplete, especially because the outcome variables are not optimally adequate. In a diagnostic study one would want to predict the diagnosis and for the accuracy the performance (discrimination, calibration, and validation) is important. Response 5 -1. Thank you for providing your valuable inputs. Because almost all index tests are only for discrimination, we will validate the discrimination performance only, and therefore will not evaluate calibration. Please view the referenced articles of diagnostic models in the "Index tests" section (page 14 -17). ME: We do not completely understand what the authors mean to say in their response. Once again we would like to refer to the book by Steyerberg, referenced above.
Response 5 -2. Thank you for your insightful comment. We have added a few sentences regarding the statistical models to compare NPV, sensitivity, and effectiveness (page 20, line 4 -5). Please see our response 2 as well. Because our study is exploratory, we will not adjust for multiple comparisons. ME: We do not understand which "few sentences" the authors are referring to. The definition of effectiveness is inadequate; NPV and sensitivity are not appropriate outcomes; and validation of prediction models is not an exploratory exercise.
Quite nicely the TRIPOD checklist was included. However, some very important matters have somehow been overlooked: 1) The title is not appropriate. Response 1) Thank you for your valuable suggestion. We have changed the title to clarify that our study is a validation study as follows, "A comprehensive validation of very early rule-out strategies for non-ST elevation myocardial infarction in emergency departments: protocol for a multicenter prospective cohort study" (page 1, line 1 -3). ME: How is the validation to be done?
2) The abstract is sub-optimal. Response 2) Thank you for your suggestion. We have revised a sentence accordingly to clarify our objective and study design as follows, "Therefore, our objective in this prospective cohort study is to comprehensively validate the diagnostic accuracy of clinical impression-based strategies, prediction-rules, and hs-troponinbased strategies for ruling-out NSTEMIs" (page 3, line 7 -10).
Because this article is a study protocol, we think that sections on statistical analysis, results, and conclusions are not necessary for the abstract. Otherwise, we have explained all the items which the TRIPOD requires such as the setting, participants, sample size, predictors, and outcome.
3) The rationale for a multivariable prediction model should be elaborated on. Does one want to develop a new model or validate existing ones? Or extend existing models and do a decision curve analysis? Response 3) Thank you for your valuable comments. Please refer to our response 2 which explains that our purpose is to validate existing models. Because we will validate only the discrimination performance, as we explained in our response 5 -1, we have observed that we cannot use a decision curve analysis. We have deleted the decision curve analysis from the "Data analysis" section (page 20). ME: How is the validation to be done?
4) Source of data should not only be mentioned in the abstract, but receive extensive attention in the methods (and materials) section. Response 4) Thank you for your critical and valuable suggestion. We agree with you and have added a section "Setting" in the methods (page 9, line 2 -7). ME: Please elaborate on the selected hospitals and how they were selected. Why are further hospitals to be added and how are they going to be selected? Which patients will be recruited and in which manner? Which differences will there be in the recruitment? What about quality control of recruitment?
6) Reconsider issues concerning the outcome. Response 6) Because our purpose is only to evaluate the discrimination performance, we think the outcomes are valid. All the original articles of index tests adopted similar outcomes as ours (sensitivity, specificity, positive predictive value, negative predictive value, and effectiveness). ME: For validation of prediction models this is insufficient.
7) More details are needed about the predictors of the models. Response 7) Thank you for the helpful suggestion. We have explained the details of the predictors of each model in the supplementary appendix.
8) Please reconsider the sample size estimation based on the outcome. Response 8) Thank you for your valuable comment. As we explained in our response 6), we think the outcomes are valid. Our primary purpose is not comparison, but description of the diagnostic accuracy of each model. Therefore, we made the sample size estimation based on accuracy. We chose the clinical impression-strategy for the sample size estimation, because it is supposed to be the most common approach in Japan (page 6, line 9 -10) ME: Model validation implies comparison, otherwise it makes little sense.
9) Missing data are a bit neglected in the protocol, simply working with a complete case approach (handling lost to follow-up as missing) is not very sound. Think about applying multiple imputation techniques. Response 9) You have raised the important point, however, we think that patients with imputed outcomes should be excluded from analysis anyway, because using imputed outcomes only adds noise to the estimates. (13, 14) We have recognized the significance of lost to follow-up from the beginning. We could follow-up 99% of patients in our preliminary study, and we have made more efforts to prevent it in this study. Therefore, we expect that the number of patients lost to follow-up will be very few. ME: Missing data is not only about outcomes, but also predictors. 12) If doing validation, then differences from the development data must be carefully looked at. Response 12) Thank you very much for providing this suggestion. We will certainly evaluate the development data in the "Discussion" section in the article of our primary analysis.
As a minor point, on page 17 it is stated: "Because Radiometer troponin T is less sensitive than Abbott ARCHITECT hs-troponin I and therefore, we generally prioritize the result of hs-troponin I if the results of the two types troponin are discordant". Logically speaking then, it would seem that Radiometer troponin T is irrelevant. If so, why is it presented in the first place? Response: Thank you for your comment. We agree with you. We have deleted Radiometer troponin T, and will use each of hstroponin for the adjudication. We will use the same hs-troponin to adjudicate the final diagnosis as that used for index tests to avoid unequal incorporation bias (page 18, line 11 -18). 
VERSION 2 -AUTHOR RESPONSE
Reviewer 1 Dr. João Gonçalves Almeida
No additional comments.
We thank the reviewer for the positive response.
============================================================================= =========================== Reviewer 2 Dr. Karol Makowski
The Authors have given the exhaustive response to the reviewer comment. First of all, we thank the reviewer for the insightful comments. However, we would like to make it clear that our study evaluates the diagnostic accuracy of existing prediction rules and that our study design follows the framework of diagnostic studies. We agree with the importance of the reviewer's comments, but they are mainly from the viewpoint of studies on prediction rules. We think these points do not fit our study well. It might be inappropriate to use the TRIPOD checklist for studies on the prediction model. We have attached the STARD checklist for diagnostic studies, which we believe is more suitable for our study design. We would appreciate it if the reviewer took a second thought on these issues. We believe that the previous studies published in medical journals have similar designs and outcomes as those in the present study. (1)(2)(3)(4)(5) -
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
1 -The rationale for or the reasons why the hs-troponin-based strategies should be evaluated and compared remain somewhat unclear.
ME: We are not convinced. Prediction models based on only one predictor are very uncommon; it is more like testing only one biomarker. This does not look like state-of-the-art prediction model building. We would recommend:
Ewout W. Steyerberg (2009): Clinical prediction models; a practical approach to development, validation, and updating; Springer-Verlag, New York Response 1: Thank you for the comment and introducing us to the book. We agree with you that prediction models based on only one predictor are uncommon. However, there are several reasons why the hs-troponin-based strategies rely only on hs-troponin. There are many multivariable prediction models for myocardial infarction in the emergency department. Although the reliability of hs-troponin is excellent, the reliability of clinical history and ECG is not good enough,(6) and they can dilute accuracy. (7) The authors who derived the hs-troponin-based strategies have examined the additive value of other predictors, such as age, history, and ECG. The additional predictors did not improve the accuracy, but rather reduced the effectiveness.(3)(8) Therefore, many clinicians working in the emergency department have a strong interest in the hs-troponin-based strategies nowadays. Studies on hs-troponin-based strategies have recently been published, (1)(9) and the guideline of the European Society of Cardiology has recognised the significance of the 0 h and 1 h model. (10) We would like to evaluate their diagnostic accuracy from a clinical perspective in Japan.
-
Response 2. Thank you for your suggestion. Our study is exploratory, and we do not have a strong prior hypothesis regarding which strategy is better. Thus, we would like to validate existing models comprehensively. We have revised some sentences in the "Rationale for the study" section (page 7, line 15 -17) to explain it. ME: Validating (and possibly updating) existing prediction models is not exploratory research. The rest of the response is thereby inadequate.
Response 2: We admit it was incorrect to describe our comparisons as "exploratory". There are many diagnostic strategies to rule out non-ST elevation myocardial infarction, and presently, we do not know which one is better. From a clinical perspective, we believe that the comprehensive validation of all existing diagnostic strategies is keenly needed. Collins et.al supported the idea of comprehensive validation in an editorial. (11) -
ME:
That is what worries us, since we got the impression different strategies are to be compared. However, the choice of strategy is based on the preference of the clinicians involved and not on chance allocation. Thus subjective aspects and considerations are involved and selection bias might be a problem.
Response 3: We appreciate the opportunity to clarify this point. All the index tests will be applied to a patient irrespective of the preference of clinicians after we complete patient recruitment; therefore, selection bias will not be a problem. The management of a patient is left to the discretion of a treating clinician when a patient visits the emergency department. We have added some sentences to the "Index tests" section (page 13, line 20-21) as follows "All the index tests will be applied to a patient using prospectively collected clinical information after we complete patient recruitment". We hope this answer would satisfy you.
How representative are the five hospitals?
Response 4. Thank you for the important question. All emergency departments of five study hospitals treat all kinds of patients, and this ensures the representativeness of the emergency department. Although four of the five study hospitals are in a specific region in Japan, there are few reports that patients' characteristics in the region differ from those in other regions, and we will be enrolling further hospitals in other regions in Japan. Therefore, we believe that our study population will be representative. We would like to discuss this issue in the "Discussion" section of our main analysis article. ME: So the hospitals involved have not been selected at random. This might compromise the validity to some extent.
Response 4: Thank you for the comment. The hospitals were not selected at random, and it might compromise the representativeness. In the real world, it is impossible to choose the hospitals out of all the eligible hospitals in Japan. We have purposively selected a number of hospitals which cover the majority of emergency cases in the rural as well as urban to suburban areas. We therefore believe that we will be able to recruit representative cases of suspected myocardial infarction patients in these areas, which are readily generalizable to the rest of Japan. We would like to discuss this issue in the "Discussion" section of our main analysis article.
The section on the data analysis is rather incomplete, especially because the outcome variables are not optimally adequate. In a diagnostic study one would want to predict the diagnosis and for the accuracy the performance (discrimination, calibration, and validation) is important.
Response 5 -1. Thank you for providing your valuable inputs. Because almost all index tests are only for discrimination, we will validate the discrimination performance only, and therefore will not evaluate calibration. Please view the referenced articles of diagnostic models in the "Index tests" section (page 14 -17). ME: We do not completely understand what the authors mean to say in their response. Once again we would like to refer to the book by Steyerberg, referenced above.
Response 5-1: We appreciate your suggestions. However, the framework of our study follows that of diagnostic studies as we have mentioned at the beginning. We believe the outcome variables satisfy the requirement of the STARD guideline for diagnostic studies. (12) Studies that adopted similar outcomes as ours have been previously published.(1)(2)(3)(4)(5)(8) (9) -
The way things are presented it is ambiguous how the various models are to be compared statistically and multiple testing might be a problem.
Response 5 -2. Thank you for your insightful comment. We have added a few sentences regarding the statistical models to compare NPV, sensitivity, and effectiveness (page 20, line 4 -5) . Please see our response 2 as well. Because our study is exploratory, we will not adjust for multiple comparisons. ME: We do not understand which "few sentences" the authors are referring to (5-2-1). The definition of effectiveness is inadequate (5-2-2); NPV and sensitivity are not appropriate outcomes (5-2-3); and validation of prediction models is not an exploratory exercise (5-2-4).
Response 5-2: Thank you for your suggestion. We have replied to each of the questions below, (5-2-1) The sentence is "We will derive a generalised score statistic to compare NPV, and use the McNemar's test to compare sensitivity and effectiveness" (page 20, line 15-16).
(5-2-2) Because we have already defined effectiveness in the "Study objectives" section (page 8, line 10 -12) as follows, "effectiveness (defined as the proportion of patients categorized into low risk to all patients to whom a strategy was applied)", we avoided defining it again.
(5-2-3) Please see the previous response 5-1.
(5-2-4) Please see the previous response 2.
Response 1) Thank you for your valuable suggestion. We have changed the title to clarify that our study is a validation study as follows, "A comprehensive validation of very early rule-out strategies for non-ST elevation myocardial infarction in emergency departments: protocol for a multicenter prospective cohort study" (page 1, line 1 -3). ME: How is the validation to be done?
Response 1): Thank you for your question. We will validate the diagnostic accuracy of the index tests following the formal methods recommended by the STARD guidelines.
Response 3) Thank you for your valuable comments. Please refer to our response 2 which explains that our purpose is to validate existing models. Because we will validate only the discrimination performance, as we explained in our response 5 -1, we have observed that we cannot use a decision curve analysis. We have deleted the decision curve analysis from the "Data analysis" section (page 20). ME: How is the validation to be done?
Response 3): Please see the previous response 1).
Source of data should not only be mentioned in the abstract, but receive extensive attention in the methods (and materials) section.
Response 4) Thank you for your critical and valuable suggestion. We agree with you and have added a section "Setting" in the methods (page 9, line 2 -7). ME: Please elaborate on the selected hospitals and how they were selected (4-1). Why are further hospitals to be added and how are they going to be selected?(4-2) Which patients will be recruited and in which manner?(4-3) Which differences will there be in the recruitment?(4-4) What about quality control of recruitment? (4) (5) Response: Thank you for the suggestion. We have replied to each of the questions below, (4-1) Please see the previous response 4. As suggested, we have added a sentence as follows, "We have purposively selected hospitals which cover the majority of emergency cases in the rural as well as urban to suburban areas" (page 9, line 7-8).
(4-2) Because the recruitment of patients is slow, we are adding new hospitals. We have added a sentence: "Because patient recruitment is slow, we are adding a number of hospitals" (page 9, line 6-7).
(4-3, 4-4) Please see the "Inclusion criteria", "Exclusion criteria" and "Participant recruitment" sections (page 9, line 10 -page 10, line 21). We have already described the details of participants and recruitment.
(4-5) We have been regularly reviewing the patient recruitment status by checking clinical records of all patients who visit the emergency department in all hospitals to ensure representativeness and minimise spectrum bias. We have also been checking all case report forms immediately after we receive them from hospitals. If there are some missing values, we have asked co-researchers and made efforts to retrieve them as much as possible. We have added these explanations in the "Participants recruitment" (page 10, line 21-24) and "Clinical assessments" (page 12, line 2-5) sections.
Reconsider issues concerning the outcome.
Response 6) Because our purpose is only to evaluate the discrimination performance, we think the outcomes are valid. All the original articles of index tests adopted similar outcomes as ours (sensitivity, specificity, positive predictive value, negative predictive value, and effectiveness). ME: For validation of prediction models this is insufficient.
Response 6): Please see the previous response 5-1.
Please reconsider the sample size estimation based on the outcome.
Response 8) Thank you for your valuable comment. As we explained in our response 6), we think the outcomes are valid. Our primary purpose is not comparison, but description of the diagnostic accuracy of each model. Therefore, we made the sample size estimation based on accuracy. We chose the clinical impression-strategy for the sample size estimation, because it is supposed to be the most common approach in Japan (page 6, line 9 -10) ME: Model validation implies comparison, otherwise it makes little sense.
Response 8): Although we agree with the importance of your comment, the description of the diagnostic accuracy of each model will not necessarily make little sense. Please see the studies that validated several diagnostic models and described the diagnostic accuracy.(4)(5)(13) We believe that these articles are helpful to many clinicians.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
9) Missing data are a bit neglected in the protocol, simply working with a complete case approach (handling lost to follow-up as missing) is not very sound. Think about applying multiple imputation techniques.
Response 9) You have raised the important point, however, we think that patients with imputed outcomes should be excluded from analysis anyway, because using imputed outcomes only adds noise to the estimates. (13, 14) We have recognized the significance of lost to follow-up from the beginning. We could follow-up 99% of patients in our preliminary study, and we have made more efforts to prevent it in this study. Therefore, we expect that the number of patients lost to follow-up will be very few. ME: Missing data is not only about outcomes (9)-1), but also predictors (9) 9)-1 Thank you for introducing these helpful articles; however, we believe that imputation is not very appropriate for outcomes of observational studies. We have consulted a statistician, and he said imputing outcomes is useful in limited situations such as randomised controlled trials when auxiliary variables with strong correlation with outcomes (e.g., intervention) are available. We have quoted some sentences from an article regarding this issue [Ian White, et.al. (14) ]: "It is argued that individuals with imputed outcomes should be excluded from the analysis, because including them only adds noise to the estimates", "Method (ii) (= multiple imputation) might be valuable when auxiliary variables have been used in the imputation model, because there is extra information in the imputed outcomes. In practice, however, it is only worth using method (ii) if auxiliary variables are highly correlated with the outcome variable (for standard error reduction)" (page 388-389). We hope this response is satisfactory.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
10) Please look carefully again at the methods and maybe employ a statistician or an epidemiologist to help out.
Response 10) Thank you for your kind suggestion. We have a statistician on our team and will consult him if necessary. ME: It is already necessary to consult him, especially to plan the application of the methods correctly, as presented by Steyerberg in his book (reference given above) and to look into Ann Intern Med 2019;170:51-58 (PROBAST: a tool to assess the risk of bias and applicability of prediction model studies) and Ann Intern Med 2019;170:W1-W33 (PROBAST: a tool to assess the risk of bias and applicability of prediction model studies: explanation and elaboration).
Response 10): Thank you for introducing the article. However, the PROBAST is for prediction model studies, and it will not be suitable for our study. Instead, we have checked the QUADAS-2 for diagnostic accuracy studies,(15) and we believe that our protocol satisfies its requirements.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
